Oral Wegovy’s UK Rollout Puts Novo Nordisk’s Pivot to the Pill to the Test

Novo Nordisk's oral semaglutide Wegovy hits UK pharmacy shelves, with 10,000 pre-orders. Priced £79-£229/month, NHS access delayed to 2028. US Medicare pilot caps copays at $50, while Eli Lilly and others intensify competition.

Novo Nordisk’s long-anticipated shift from injection to tablet enters its most public phase this week, with the oral formulation of Wegovy hitting pharmacy shelves across Britain. The move marks the first time the Danish drugmaker has offered a daily GLP-1 pill for weight loss in a major European market, and early demand signals are hefty. Simple Online Pharmacy alone has logged more than 10,000 pre-orders, while the National Pharmacy Association has already warned patients to beware of counterfeit products and to seek medical supervision before starting the regimen.

Pricing varies by dose, reflecting a tiered strategy to keep the drug accessible while maximising revenue per patient. The starting strength of 1.5 mg costs between £79 and £99 per month, while higher maintenance doses can reach up to £229 for the top tier. For now the drug is available only through private pharmacies; NHS patients will have to wait until 2028 for coverage. That lag gives Novo Nordisk a window to prove the tablet’s commercial viability in a real-world setting before the state healthcare system steps in.

The clinical data underpinning the launch are robust. Over 64 weeks, patients taking the oral semaglutide lost 13.61% of their body weight, compared with 2.18% in the placebo group. The drug is indicated for people with a body-mass index of 30 or higher, or 27 with at least one weight-related comorbidity. The convenience of a daily pill could expand the addressable patient pool well beyond the injection crowd, but the price tag — especially for patients paying out of pocket — will test how much elasticity the market truly has.

Across the Atlantic, the US market is adding its own tailwind. Since July 1, a pilot programme known as the Medicare GLP-1 Bridge has capped monthly copays at $50 for eligible Part D beneficiaries. The initiative, which runs through the end of 2027, covers roughly four million seniors and is expected to supercharge demand for GLP-1 therapies in the second half of the year. Novo Nordisk is already responding by preparing single-dose vials of Wegovy that would be cheaper and more flexible than the current prefilled pens, a move aimed at fending off price pressure from rivals.

Those rivals are not standing still. Eli Lilly now controls about 60% of the global GLP-1 market, leaving Novo Nordisk with a 40% share. Lilly’s injectable Zepbound has posted strong prescription growth in 2025, and its oral candidate Foundayo secured FDA approval in early 2026, priced at $149 a month without insurance. On the pipeline front, Structure Therapeutics recently reported positive phase 2b data for its own oral candidate, aleniglipron, and expects to kick off a phase 3 study in the third quarter of 2026. That timeline keeps the competitive pressure on Novo Nordisk to nail the launch and defend its turf.

The company also scored a regulatory win at the weekend when the UK’s Medicines and Healthcare products Regulatory Agency granted conditional approval for Wegovy to treat the fatty-liver disease MASH. The decision builds on earlier evidence that semaglutide can lower the risk of major cardiovascular events. Expanding the drug’s label beyond weight loss not only opens a new revenue stream but also strengthens the argument for physicians to prescribe it more broadly.

At the stock level, the flurry of positive headlines has propelled a sharp recovery. Novo Nordisk closed Friday at €43.50, a gain of 16.72% over the past 30 days and 2.90% for the week. Yet the year-to-date picture remains negative, with the shares still off 2.64% since January. The 12-month decline stands at 26.55%, and the stock trades nearly 29% below its 52-week high of €61.20 reached in July 2025. The recent run-up has pushed the 14-day relative strength index to 71.2, a level many technicians consider overbought. More tellingly, the equity now sits 12.33% above its 50-day moving average of €38.72 — a spread that often precedes a consolidation phase.

For Novo Nordisk, the UK launch is not just a new chapter but a test case for how the oral format can translate into sustained revenue in Europe. With more than three million prescriptions already filled globally for the tablet and the majority of those coming from first-time GLP-1 users, the potential to convert new patients is clear. But against Eli Lilly’s powerful market share, the constraints of NHS waiting lists, and a growing pipeline of competitors, the next few months will reveal whether the pill truly changes the game or simply adds another front to an increasingly crowded war.